Continuous Medical Grade Diagnostics for All People Through Clothing
The initiation of clinical trials aims to validate the use of Skiin as a medical device with numerous form factors ranging from 3-lead ECG-enabled undergarments to 12-lead ECG Holter monitor vests, ushering in a new paradigm in remote patient monitoring and the democratization of healthcare. As part of these studies, Myant will be validating the ECG signal acquired through its textile based sensory system as well as incorporating other biometrics (like respiration, temperature, biomechanics, etc.) and contextual information (like activity, location, and more) to provide a holistic view on a patient’s health and well-being which can be used by healthcare professionals and caregivers to better anticipate and prevent medical conditions before they manifest as acute or chronic issues.
Clinical Trial with PACE Cardiology (Southlake Regional Health Centre)
Skiin: From Wellness Product to Medical Device and Beyond
“This clinical trial is an important step in Myant’s roadmap of providing access to healthcare, continuously and seamlessly, with the objective of obtaining Health Canada and FDA approval for the classification of Skiin as a Class II medical device. Through this trial, and others being planned, we are demonstrating the potential of our textile computing platform which serves as a medium for the collection and delivery of continuous biometrics. These garments will be the first of many, enabling the promise of telemedicine and working towards reducing the disparity in access to health care world wide,” said Milad Alizadeh-Meghrazi, VP of R&D at Myant.
The classification of Skiin as a medical device will come at a time when the ability to remotely access healthcare is more relevant than ever. Myant was recently announced as a recipient of federal funding for the development and deployment of Skiin as a response to the COVID-19 pandemic, enabling those in remote communities to access care without having to risk exposure by travelling to points of care. Subsequent to this trial, Myant will also be introducing and testing additional sensory capabilities (e.g. SpO2 measurement, pulse wave analysis, blood pressure, and digital stethoscope capabilities) which will provide physicians, nurses and caregivers an even more comprehensive understanding of the physiological state of the patient.
For more information about clinical trials or Myant, please contact:
Dr. Bastien Moineau, MSc, PT, PhD
R&D Lead, Rehabilitation and Physiotherapy Specialist @ Myant
Milad Alizadeh-Meghrazi, MASc, PhD (c)
Vice President of Research, Development and Partner Integration @ Myant
Executive Vice President
About Myant Inc.
Myant has created the world’s first Textile Computing platform that continuously and ambiently connects people to their bodies, to each other, and to the world around them. Using connected textiles that can sense and react to the human body and a platform that enables machine learning driven health and performance outcomes, Myant is on a mission to transform human connectedness. With an extensive patent portfolio, key exclusive relationships within the textile computing industry, a multidisciplinary team of researchers, engineers, data scientists, fashion designers and knitting specialists, and over 80,000 ft² of manufacturing capacity, Myant is changing the way people across society connect. Connect with us to find out how we can help you create innovative solutions powered by connected textiles and the Myant Platform.
For more information about Myant, please visit www.myant.ca.